



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Ablation of prion protein in wild type human amyloid precursor protein (APP) transgenic mice does not alter the proteolysis of APP, levels of amyloid- or pathologic phenotype

Citation for published version:

Whitehouse, I, Brown, D, Baybutt, H, Diack, A, Piccardo, P, Manson, J & Hooper, NM 2016, 'Ablation of prion protein in wild type human amyloid precursor protein (APP) transgenic mice does not alter the proteolysis of APP, levels of amyloid- or pathologic phenotype', *PLoS ONE*, vol. 11, no. 7, e0159119. <https://doi.org/10.1371/journal.pone.0159119>

Digital Object Identifier (DOI):

[10.1371/journal.pone.0159119](https://doi.org/10.1371/journal.pone.0159119)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

PLoS ONE

Publisher Rights Statement:

© 2016 Whitehouse et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



RESEARCH ARTICLE

Ablation of Prion Protein in Wild Type Human Amyloid Precursor Protein (APP) Transgenic Mice Does Not Alter The Proteolysis of APP, Levels of Amyloid- β or Pathologic Phenotype

Isobel J. Whitehouse^{1*}, Deborah Brown^{2*}, Herbert Baybutt², Abigail B. Diack², Katherine A. B. Kellett³, Pedro Piccardo², Jean C. Manson^{2*}, Nigel M. Hooper^{3*}

1 School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, Leeds, United Kingdom, **2** The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Roslin, Midlothian, United Kingdom, **3** Institute of Brain, Behaviour and Mental Health, Faculty of Medical and Human Sciences, University of Manchester, Manchester, United Kingdom

* These authors contributed equally to this work.

* jean.manson@roslin.ed.ac.uk (JM); nigel.hooper@manchester.ac.uk (NH)



OPEN ACCESS

Citation: Whitehouse IJ, Brown D, Baybutt H, Diack AB, Kellett KAB, Piccardo P, et al. (2016) Ablation of Prion Protein in Wild Type Human Amyloid Precursor Protein (APP) Transgenic Mice Does Not Alter The Proteolysis of APP, Levels of Amyloid- β or Pathologic Phenotype. PLoS ONE 11(7): e0159119. doi:10.1371/journal.pone.0159119

Editor: Roberto Chiesa, IRCCS - Mario Negri Institute for Pharmacological Research, ITALY

Received: May 12, 2016

Accepted: June 27, 2016

Published: July 22, 2016

Copyright: © 2016 Whitehouse et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper.

Funding: The authors gratefully acknowledge the financial support of Alzheimer's Research UK (ART-PPG2009B-8), and the Medical Research Council of Great Britain (G0802189) and the University of Manchester. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Abstract

The cellular prion protein (PrP^C) has been proposed to play an important role in the pathogenesis of Alzheimer's disease. In cellular models PrP^C inhibited the action of the β -secretase BACE1 on wild type amyloid precursor protein resulting in a reduction in amyloid- β (A β) peptides. Here we have assessed the effect of genetic ablation of PrP^C in transgenic mice expressing human wild type amyloid precursor protein (line I5). Deletion of PrP^C had no effect on the α - and β -secretase proteolysis of the amyloid precursor protein (APP) nor on the amount of A β 38, A β 40 or A β 42 in the brains of the mice. In addition, ablation of PrP^C did not alter A β deposition or histopathology phenotype in this transgenic model. Thus using this transgenic model we could not provide evidence to support the hypothesis that PrP^C regulates A β production.

Introduction

Alzheimer's disease (AD) is the most common form of dementia affecting 30 million individuals world-wide [1,2]. Age is the greatest risk factor for AD, with the incidence doubling every 5 years after age 65. Therefore, with our ageing population, AD is placing immense financial and social pressure on society. Currently there are no treatments that either cure or halt the progression of this neurodegenerative disease [3]. The majority (>95%) of AD cases have no underlying genetic mutation and are referred to as sporadic or late-onset AD [4]. In a small proportion of cases, mutations in the genes encoding the amyloid precursor protein (APP) or presenilin (PS) 1 or PS2 give rise to early onset, familial AD [4]. The disease is characterised by the deposition in the brain of extracellular plaques of amyloid- β (A β) which is derived from the proteolytic processing of APP [5], along with intracellular neurofibrillary tangles of

Competing Interests: The authors have declared that no competing interests exist.

Abbreviations: A β , amyloid- β ; AD, Alzheimer's disease; APP, amyloid precursor protein; BACE1, β -site APP cleaving enzyme-1; PrP^C, prion protein.

hyperphosphorylated tau protein [6]. APP is cleaved first by the β -secretase, β -site APP cleaving enzyme-1 (BACE1), and then by the PS-containing γ -secretase complex to release A β , the predominant forms of which are 40 or 42 amino acids in length (A β ₄₀ and A β ₄₂, respectively) [5].

Cleavage of APP by BACE1 is the rate-limiting step in A β production [7] and various cellular proteins have been reported to influence this step, including the cellular form of the prion protein (PrP^C) [8]. PrP^C inhibited the action of BACE1 on wild type APP (APP_{WT}) in various cellular models, in part through glycosaminoglycan-mediated interaction at the cell surface and in part through retaining the pro-domain containing form of BACE1 in the early secretory pathway [8,9]. In the brains of PrP^C null mice there was a significant increase in the amount of endogenous murine A β [8], consistent with PrP^C having a role in regulating the production of A β from APP *in vivo*. Together with the observation that PrP^C was decreased in the brains from sporadic AD individuals and that the amount of PrP^C inversely correlated with BACE1 activity, soluble and insoluble A β and Braak stage in the human brain [10,11], led us to propose that PrP^C may function to protect against AD and that loss of PrP^C would lead to the earlier onset of AD [12,13].

The inhibitory effect of PrP^C on the BACE1 cleavage of APP was only apparent on APP_{WT} and was lost on APP with the Swedish double point mutation adjacent to the BACE1 cleavage site (APP_{Swe}) [9]. APP_{Swe} is subject to BACE1 cleavage in the secretory pathway [14,15] rather than in the endosomal pathway as for APP_{WT} [16,17]. As PrP^C interacted directly with the pro-domain of the immature Golgi-localised form of BACE1, decreasing the amount of BACE1 at the cell surface and in endosomes, this provided a mechanism to explain the differential inhibitory effect of PrP^C towards APP_{WT} and APP_{Swe} [9]. In transgenic mice expressing human APP_{Swe,Ind} we [9] and others [18–20] have reported that upon genetic ablation of PrP^C there is no alteration in APP processing, A β levels or plaque pathology, consistent with this differential inhibitory mechanism. Therefore, in this study we aimed to determine whether ablation of PrP^C in transgenic mice expressing human APP_{WT} results in increased A β and subsequently causes the premature appearance of plaque pathology.

Materials and Methods

Transgenic Animals

Transgenic APP_{WT} mice over expressing human wild-type APP (line I5) or APP_{Swe,Ind} mice over expressing human APP with the Swedish (K670N/M671L) and Indiana (V717F) familial AD mutations (line J20) [21] were obtained from The Jackson Laboratory, (Line B6.Cg-Tg (PDGFB-APP)5Lms/J, stock number 004662 and B6.Cg-Tg(PDGFB-APP_{Swe,Ind})20Lms/2J, stock number 006293, respectively) and The J. David Gladstone Institutes, San Francisco, CA 94158) and crossed with inbred PrP knockout mice (129Ola PrP^{-/-}) [22]. The genetic background of all mice used in this study was mixed B6/129Ola and only female mice were used. Operators were blinded to genotype and animals were randomly assigned to cages of n = 4 and given access to food and water ad libitum. During housing, animals were monitored daily for health status and no adverse effects were noted. All the transgenic mice used in this study were genotyped. DNA was prepared from ear punch tissue using a DNeasy Kit (Qiagen). PCR was performed using the protocol specific for these mice from The Jackson Laboratory. At end point, animals were culled by cervical dislocation and brain hemispheres were either frozen at -80°C for biochemical analysis or fixed in 10% formol saline for histopathological analysis. These experiments were approved by The Roslin Institute's Animal Welfare and Ethical Review Board and were conducted according to the regulations of the UK Home Office Animals (Scientific Procedures) Act 1986. All efforts were made to minimise suffering.

Homogenisation

Brain hemispheres were homogenised using a two-step extraction protocol [23]. Briefly, initial homogenisation (120 mg/ml wet weight) was carried out using an electrical homogeniser in 2% (w/v) SDS containing protease inhibitor cocktail (Roche Diagnostics GmbH, Germany) and PhosSTOP phosphatase inhibitor (Roche Diagnostics GmbH, Germany), followed by centrifugation at 100,000 g for 1 h at 4°C. The resultant supernatant (containing ‘soluble’ A β) was collected and analysed as described below. The pellet was extracted in 70% (v/v) formic acid in dH₂O followed by centrifugation at 100,000 g for 1 h at 4°C. The supernatant (containing ‘insoluble’ A β) was collected and analysed as described below.

SDS-PAGE and Immunoblot Analysis

Samples were mixed with an equal volume of SDS dissociation buffer (125 mM Tris/HCl, pH 6.8, 2% (w/v) SDS, 20% (v/v) glycerol, 100 mM dithiothreitol, 0.002% (w/v) bromophenol blue) and boiled for 5 min. Proteins from mouse brain homogenate (30 μ g) were resolved by SDS-PAGE using 7–17% polyacrylamide gradient gels. Resolved proteins were then transferred to Immobilon P polyvinylidene difluoride membrane (Amersham, Little Chalfont, UK). The membrane was blocked by incubation for 1 h with PBS containing 0.1% (v/v) Tween-20 and 5% (w/v) dried milk powder. Antibody incubations were performed in PBS-Tween containing 2% (w/v) BSA. Antibody 6D11 (Eurogentec Ltd., Liege, Belgium) recognises PrP^C, antibody Y188 (Abcam, Cambridge, UK) was used to detect full length APP and antibody AC15 (Sigma, Dorset, UK) was used to detect actin. Horseradish peroxidase (HRP)-conjugated secondary antibodies were used in the same buffer. Bound antibody was detected using the enhanced chemiluminescence detection method (Amersham Biosciences, Amersham, UK).

Measurement of A β and Soluble APP Fragments by Mesoscale Discovery Analysis

Biochemical analysis was performed on APP_{WT}/PrP^{+/+} (n = 3), APP_{WT}/PrP^{-/-} (n = 6) mice at 32 and 75 weeks of age, and APP_{Swe,Ind}/PrP^{+/+} (n = 5, 7 and 4 at 5, 10 and 40 weeks, respectively) A β peptides (A β ₃₈, A β ₄₀ and A β ₄₂) and soluble APP fragments (sAPP α and sAPP β) contained in the soluble (SDS extracted) fraction and A β peptides in the insoluble (formic acid extracted) fraction were assessed using the Mesoscale Discovery (MSD) platform. A β ₃₈, A β ₄₀ and A β ₄₂ were measured using the V-Plex A β peptide panel (6E10) kit and sAPP α and sAPP β using the sAPP α /sAPP β multiplex kit according to the manufacturer’s instructions (MSD, Maryland US). SDS samples were diluted 1:40 and formic acid samples 1:500 in diluent 35.

Histology

Pathological analysis was performed on APP_{WT}/PrP^{+/+} (n = 4), APP_{WT}/PrP^{-/-} (n = 4) and APP_{Swe,Ind}/PrP^{+/+} (n = 4) mice at 32 and 75 weeks of age (the group size dropped to an n = 1 in the 75 week APP_{WT}/PrP^{+/+} group due to intercurrent losses). Sections from a 129Ola (WT) mouse at 75 weeks of age were also analysed. Neuropathologic evaluation was performed blind by two operators. Fixed brain tissue was processed and tissue sections were prepared as described [24]. Paraffin sections (6 μ m) were stained with hematoxylin-eosin and immunostained with the following antibodies: 4G8 (1/300) raised against A β _{17–24} (Covance; SIG-39200); OC (1/500) that recognises a conformational-dependent epitope, specific to fibrils and soluble fibrillar oligomers (a gift from Professor C. Glabe, Dept. Neurology, University of California at Irvine School of Medicine, Irvine, CA, USA); anti-synaptophysin (1/150) that recognises a synaptic vesicle protein (Synaptic systems, 101002); anti-glial fibrillary acidic protein (GFAP)

(1/400) (DAKO Z0334); anti-Iba1 (1/1000) a calcium-binding protein specifically expressed in macrophages and microglia (Wako 019–9741). Primary antibody binding was detected with biotinylated goat anti-species specific IgG (Strattech Scientific Ltd.) and the Vectastain Elite ABC Kit (Vector Laboratories), visualized with diaminobenzidine. For synaptophysin immunolabelling antigen retrieval (DAKO S1699) and enhancement visualization system (EnVision™ K5007) were used. Antigen retrieval using 0.1M citrate buffer was performed with the Iba1 labelling.

Statistical Analysis

Densitometric analysis was performed using the advanced image data analyser (AIDA) programme (Raytest Scientific Ltd). The Kolmogorov-Smirnov test was used to determine that the data in each group was normally distributed. Following this the Levene's test was used to ensure that the data sets were of equal variance. In samples where the data met the criteria of a normal distribution and equal variance, the parametric independent t-test was used to calculate significance. In the samples which were not normally distributed the non-parametric two-tailed Mann-Whitney U test was used to compare two independent samples. The data were analysed using the Statistical Package for Social Sciences (SPSS 19) program (Chicago, USA).

Results and Discussion

In order to investigate whether ablation of PrP^C in transgenic mice expressing human APP_{WT} results in increased A β , mice expressing human APP_{WT} [21] were crossed with PrP^C-null 129/Ola mice [22]. Immunoblot analysis of mice at 32 and 75 weeks of age confirmed the absence of PrP^C in the APP_{WT}/PrP^{-/-} mice and that the lack of PrP^C had no effect on APP expression (Fig 1A). The amounts of the soluble APP species, sAPP α and sAPP β , were no different between the APP_{WT}/PrP^{-/-} and APP_{WT}/PrP^{+/+} mice at either 32 or 75 weeks of age (Fig 1B), indicating that deletion of PrP^C had no effect on either the α - or β -secretase cleavage of APP. There was a significant increase in sAPP α in both genotypes at 75 weeks of age compared to 32 weeks of age (Fig 1B) which resulted in an increased sAPP α :sAPP β ratio (Fig 1C). The levels of soluble (SDS-extracted) A β ₃₈, A β ₄₀ and A β ₄₂ were investigated. At both 32 and 75 weeks of age there was no difference in the amount of soluble A β ₃₈, A β ₄₀ or A β ₄₂ in the brain homogenates of the APP_{WT}/PrP^{-/-} mice compared to the APP_{WT}/PrP^{+/+} mice (Fig 1D). The amount of A β ₄₀ and A β ₄₂ was higher at 75 weeks of age than at 32 weeks of age regardless of *Prnp* genotype (Fig 1D), with a proportionately larger increase in A β ₄₂ such that the A β ₄₂:A β ₄₀ ratio increased in both the APP_{WT}/PrP^{-/-} and APP_{WT}/PrP^{+/+} mice with age (Fig 1E). The levels of A β peptides in the insoluble (formic acid extracted) fraction from either the APP_{WT}/PrP^{-/-} or the APP_{WT}/PrP^{+/+} mice were below the limit of detection in the assay. These data indicate that lack of PrP^C in transgenic mice expressing human APP_{WT} does not alter the proteolysis of APP or the levels of A β .

To investigate whether lack of PrP^C in the APP_{WT}/PrP^{-/-} mice affected the deposition of A β in the brain, histopathological analysis of the hippocampus was carried out at 32 weeks of age and compared to APP_{WT}/PrP^{+/+} mice. APP_{Swe,Ind}/PrP^{+/+} mice, which are known to accumulate limited A β -positive plaques at this age, were also analysed [9,21]. APP_{WT}/PrP^{+/+} and APP_{WT}/PrP^{-/-} mice at 32 weeks of age showed no obvious neuropathologic alterations (data not shown). To explore whether histopathologic alterations were detected in older animals, we also examined mice at 75 weeks of age. Histopathological analysis of WT, APP_{WT}/PrP^{+/+} and APP_{WT}/PrP^{-/-} mice at 75 weeks of age showed similar histopathologic features; i.e. absence of obvious neuronal loss or other obvious alterations in the hippocampus proper or dentate gyrus (Fig 2A, 2D and 2G) or 4G8 positive A β plaque formation (Fig 2B, 2E and 2H) in these mice.




Fig 1. Ablation of PrP^C does not affect APP proteolysis or A β peptide levels in APP_{WT} mice. Brain hemispheres from 32 week and 75 week old APP_{WT}/PrP^{+/+} and APP_{WT}/PrP^{-/-} mice were subjected to two-step homogenisation, and the soluble proteins (SDS extracted) were subjected to SDS-PAGE and immunoblotting. (A) representative immunoblots of PrP^C and APP, with actin as a loading control. (B) Soluble (SDS extracted) sAPP α and sAPP β detected by MSD ELISA and (C) the ratio of sAPP α to sAPP β . (D) Soluble (SDS extracted) A β 38, A β 40 and A β 42 detected by MSD ELISA and (E) the ratio of A β 42 to A β 40. Data shown as mean \pm SEM (n = 3–6). There was no significant difference between the APP_{WT}/PrP^{+/+} and APP_{WT}/PrP^{-/-} at the same time point for any of the APP or A β peptides.

doi:10.1371/journal.pone.0159119.g001




Fig 2. Ablation of PrP^C does not affect A β deposition in APP_{WT} mice. Histopathologic analysis of the hippocampus of hematoxylin-eosin stained sections of WT, APP_{WT}/PrP^{+/+} and APP_{WT}/PrP^{-/-} mice show absence of obvious alterations in the pyramidal cell layer, stratum oriens and lacunosum-molecular (A, D and G). No A β deposits are seen in sections probed with antibody 4G8 (B, E and H) or antibody OC (C, F and I). In contrast, APP_{Swe,Ind}/PrP^{+/+} mice show plaques (arrows) in sections stained with hematoxylin-eosin (J) and abundant A β -reactive deposits in sections probed with antibody 4G8 (K) and OC (L). All images x20 magnification and scale bar = 100 μ m.

doi:10.1371/journal.pone.0159119.g002

We investigated whether the ablation of PrP^C affected the level of A β fibrils and fibrillar oligomers by using the OC antibody [25]. We observed that WT, APP_{WT}/PrP^{+/+} and APP_{WT}/PrP^{-/-} mice did not accumulate OC immunopositive deposits as shown by immunohistochemistry (Fig 2C, 2F and 2I). As expected, in the APP_{Swe,Ind}/PrP^{+/+} mice at 75 weeks of age there was disruption of the hippocampal structure with accumulation of 4G8 and OC positive A β deposition forming numerous uni and multicentric plaques (Fig 2J, 2K and 2L), as seen previously [9]. Synapses are particularly vulnerable to the toxic effect of protein oligomers. Thus, we

performed immunostaining for the detection of the presynaptic protein synaptophysin and observed disruption of immunoreactivity in 75 week old APP_{Swe,Ind}/PrP^{+/+} mice but not in APP_{WT}/PrP^{+/+} or APP_{WT}/PrP^{-/-} mice (Fig 3A, 3D and 3G). Glial markers (GFAP and Iba1) showed similar intensity and pattern of reactivity in APP_{WT}/PrP^{+/+} and APP_{WT}/PrP^{-/-} mice (Fig 3B, 3C, 3E and 3F). In contrast, gliosis was observed particularly in the vicinity of amyloid deposits in APP_{Swe,Ind}/PrP^{+/+} mice (Fig 3H and 3I). Thus, we did not detect any effect of PrP^C ablation on A β deposition using immunohistochemistry.

A comparison of the A β levels between the APP_{WT}/PrP^{+/+} mice at 75 weeks of age with APP_{Swe,Ind}/PrP^{+/+} mice at 5 and 10 weeks (before significant A β deposition occurs) and at 40 weeks (after A β deposition in plaques appears) revealed that at 75 weeks of age the amount of A β peptides in the soluble (SDS extracted) fraction of the APP_{WT}/PrP^{+/+} mice was comparable to the amount of each peptide in the 5 week old APP_{Swe,Ind}/PrP^{+/+} mice (Fig 4A). Although A β ₄₀ and A β ₄₂ were readily detectable in the insoluble (formic acid extracted) fraction from the APP_{Swe,Ind}/PrP^{+/+} mice (Fig 4B), no A β was detected in the insoluble fraction from the APP_{WT}/PrP^{+/+} mice. The soluble A β ₄₂:A β ₄₀ ratio increased with age in both APP_{WT}/PrP^{+/+}




Fig 3. Ablation of PrP^C does not affect synaptophysin immunoreactivity and does not induce gliosis in APP_{WT} mice. APP_{WT}/PrP^{+/+} and APP_{WT}/PrP^{-/-} mice show retention of the pre-synaptic marker synaptophysin (A, D) while APP_{Swe,Ind}/PrP^{+/+} mice reveal disorganization of synaptophysin immunoreactivity (arrow) (G). Astrogliosis and microgliosis are observed in 75 week old APP_{Swe,Ind}/PrP^{+/+} mice, (arrows) (H, I) but not in mice expressing APP_{WT}/PrP^{+/+} and APP_{WT}/PrP^{-/-} (B, C, E, F). Section were probed with anti-synaptophysin (A, D, G), anti-GFAP (B, E, H), and anti-Iba1 (C, F, I) antibodies. Figures A,D,G (synaptophysin) x60 magnification scale bar = 20 μ m, figures B,E,H (GFAP) and C,F,I (Iba1) x40 magnification scale bar = 50 μ m.

doi:10.1371/journal.pone.0159119.g003




Fig 4. Comparison of A β levels in APP_{WT} and APP_{Swe,Ind} mice. Brain hemispheres from 75 week old APP_{WT}/PrP^{+/+} and from 5, 10 and 40 week old APP_{Swe,Ind}/PrP^{+/+} mice were subjected to two-step homogenisation. (A) Soluble (SDS extracted) and (B) insoluble (formic acid extracted) A β 38, A β 40 and A β 42 detected by MSD ELISA and (C) the ratio of A β 42:A β 40. Data shown as mean \pm SEM (n = 3–6), * p<0.05 compared to the 75 week old APP_{WT}/PrP^{+/+} group.

doi:10.1371/journal.pone.0159119.g004

and APP_{Swe,Ind}/PrP^{+/+} mice (Fig 4C) but was significantly higher in the APP_{Swe,Ind}/PrP^{+/+} mice than in the APP_{WT}/PrP^{+/+} mice consistent with the presence of the Indiana mutation increasing production of A β ₄₂ as observed previously [21]. Even at 75 weeks of age the amount of A β ₄₂ in the APP_{WT}/PrP^{+/+} mice is significantly lower than that in the APP_{Swe,Ind}/PrP^{+/+} mice at 5, 10 and 40 weeks of age (Fig 4A). Thus in the APP_{WT}/PrP^{+/+} mice even at 75 weeks of age the low level of A β ₄₂ is likely below the threshold required for deposition to occur.

Conclusion

In cellular models PrP^C differentially affected the activity of the β -secretase BACE1 towards APP_{WT} and APP_{Swe}, inhibiting the processing of the former but having no effect on the cleavage of the latter [8,9]. Thus we undertook this study in order to investigate the effect of genetic ablation of PrP^C on human APP_{WT} processing *in vivo*. In contrast to the cellular models, lack of PrP^C had no effect on the α - and β -secretase proteolysis of APP or on the amount of A β peptides in the brains of mice expressing human APP_{WT}. Also we did not detect any A β deposition as shown by immunohistochemistry in the mice lacking PrP^C as compared to those with a normal level of the protein. In the human brain the amount of PrP^C inversely correlated with BACE1 activity, soluble and insoluble A β and Braak stage [11], consistent with levels of PrP^C affecting APP processing and A β production. However, we could find no evidence that loss of PrP^C affected APP proteolysis, A β levels or plaque pathology *in vivo* in transgenic mice expressing human APP_{WT}. Whether this reflects a difference in the role of PrP^C in regulating APP processing and A β production between this transgenic mouse model and the situation in the human brain will require further study.

Author Contributions

Conceived and designed the experiments: IJW DB HB ABD KABK JCM NMH. Performed the experiments: IJW DB HB ABD KABK PP. Analyzed the data: IJW DB HB ABD KABK PP JCM NMH. Wrote the paper: IJW DB ABD KABK PP JCM NMH.

References

1. Burns A, Iliffe S. Alzheimer's disease. *BMJ*. 2009; 338: 467–471.
2. Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. *Science translational medicine*. 2011; 3: 77sr71.
3. Selkoe D, Mandelkow E, Holtzman D. Deciphering Alzheimer disease. *Cold Spring Harb Perspect Med*. 2012; 2: a011460. doi: [10.1101/cshperspect.a011460](https://doi.org/10.1101/cshperspect.a011460) PMID: [22315723](https://pubmed.ncbi.nlm.nih.gov/22315723/)
4. Walsh DM, Teplow DB. Alzheimer's disease and the amyloid beta-protein. *Progress in molecular biology and translational science*. 2012; 107: 101–124. doi: [10.1016/B978-0-12-385883-2.00012-6](https://doi.org/10.1016/B978-0-12-385883-2.00012-6) PMID: [22482449](https://pubmed.ncbi.nlm.nih.gov/22482449/)
5. Vardy ER, Catto AJ, Hooper NM. Proteolytic mechanisms in amyloid-beta metabolism: therapeutic implications for Alzheimer's disease. *Trends Mol Med*. 2005; 11: 464–472. PMID: [16153892](https://pubmed.ncbi.nlm.nih.gov/16153892/)
6. Lee VM, Brunden KR, Hutton M, Trojanowski JQ. Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets. *Cold Spring Harb Perspect Med*. 2011; 1: a006437. doi: [10.1101/cshperspect.a006437](https://doi.org/10.1101/cshperspect.a006437) PMID: [22229117](https://pubmed.ncbi.nlm.nih.gov/22229117/)
7. Cole SL, Vassar R. The Alzheimer's disease Beta-secretase enzyme, BACE1. *Mol Neurodegener*. 2007; 2: 22 PMID: [18005427](https://pubmed.ncbi.nlm.nih.gov/18005427/)
8. Parkin ET, Watt NT, Hussain I, Eckman EA, Eckman CB, Manson JC, et al. Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. *Proc Natl Acad Sci USA*. 2007; 104: 11062–11067. PMID: [17573534](https://pubmed.ncbi.nlm.nih.gov/17573534/)
9. Griffiths HH, Whitehouse IJ, Baybutt H, Brown D, Kellett KAB, Jackson CD, et al. Prion Protein Interacts with BACE1 Protein and Differentially Regulates Its Activity toward Wild Type and Swedish Mutant Amyloid Precursor Protein. *J Biol Chem*. 2011; 286: 33489–33500. doi: [10.1074/jbc.M111.278556](https://doi.org/10.1074/jbc.M111.278556) PMID: [21795680](https://pubmed.ncbi.nlm.nih.gov/21795680/)

10. Whitehouse IJ, Jackson CD, Turner AJ, Hooper NM. Prion protein is reduced in aging and in sporadic but not in familial Alzheimer's disease. *J Alzheimers Dis*. 2010; 22: 1023–1031. doi: [10.3233/JAD-2010-101071](https://doi.org/10.3233/JAD-2010-101071) PMID: [20930299](https://pubmed.ncbi.nlm.nih.gov/20930299/)
11. Whitehouse IJ, Miners JS, Glennon EB, Kehoe PG, Love S, Kellett KA, et al. Prion protein is decreased in Alzheimer's brain and inversely correlates with BACE1 activity, amyloid-beta levels and Braak stage. *PLoS One*. 2013; 8: e59554. doi: [10.1371/journal.pone.0059554](https://doi.org/10.1371/journal.pone.0059554) PMID: [23577068](https://pubmed.ncbi.nlm.nih.gov/23577068/)
12. Hooper NM, Turner AJ. A new take on prions: preventing Alzheimer's disease. *Trends Biochem Sci*. 2008; 33: 151–155. doi: [10.1016/j.tibs.2008.01.004](https://doi.org/10.1016/j.tibs.2008.01.004) PMID: [18343669](https://pubmed.ncbi.nlm.nih.gov/18343669/)
13. Griffiths HH, Whitehouse IJ, Hooper NM. Regulation of amyloid-beta production by the prion protein. *Prion*. 2012; 6: 217–222. doi: [10.4161/pr.18988](https://doi.org/10.4161/pr.18988) PMID: [22449984](https://pubmed.ncbi.nlm.nih.gov/22449984/)
14. Haass C, Lemere CA, Capell A, Citron M, Seubert P, Schenk D, et al. The Swedish mutation causes early-onset Alzheimer's disease by b-secretase cleavage within the secretory pathway. *Nature Med*. 1995; 1: 1291–1296. PMID: [7489411](https://pubmed.ncbi.nlm.nih.gov/7489411/)
15. Thinakaran G, Teplow DB, Siman R, Greenberg B, Sisodia SS. Metabolism of the 'Swedish' amyloid precursor protein variant in Neuro2a (N2a) cells. Evidence that cleavage at the 'b-secretase' site occurs in the Golgi apparatus. *J Biol Chem*. 1996; 271: 9390–9397. PMID: [8621605](https://pubmed.ncbi.nlm.nih.gov/8621605/)
16. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. b-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. *Science*. 1999; 286: 735–741. PMID: [10531052](https://pubmed.ncbi.nlm.nih.gov/10531052/)
17. Huse JT, Pijak DS, Leslie GJ, Lee VM, Doms RW. Maturation and endosomal targeting of beta-site amyloid precursor protein-cleaving enzyme. THE ALZHEIMER'S DISEASE beta-SECRETASE. *J Biol Chem*. 2000; 275: 33729–33737. PMID: [10924510](https://pubmed.ncbi.nlm.nih.gov/10924510/)
18. Calella AM, Farinelli M, Nuvolone M, Mirante O, Moos R, Falsig J, et al. Prion protein and Abeta-related synaptic toxicity impairment. *EMBO Mol Med*. 2010; 2: 306–314. doi: [10.1002/emmm.201000082](https://doi.org/10.1002/emmm.201000082) PMID: [20665634](https://pubmed.ncbi.nlm.nih.gov/20665634/)
19. Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Lauren J, Gimbel ZA, et al. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. *J Neurosci*. 2010; 30: 6367–6374. doi: [10.1523/JNEUROSCI.0395-10.2010](https://doi.org/10.1523/JNEUROSCI.0395-10.2010) PMID: [20445063](https://pubmed.ncbi.nlm.nih.gov/20445063/)
20. Cisse M, Sanchez PE, Kim DH, Ho K, Yu GQ, Mucke L. Ablation of cellular prion protein does not ameliorate abnormal neural network activity or cognitive dysfunction in the J20 line of human amyloid precursor protein transgenic mice. *The Journal of neuroscience: the official journal of the Society for Neuroscience*. 2011; 31: 10427–10431.
21. Mucke L, Masliah E, Yu G-Q, Mallory M, Rockenstein EM, Tatsuno G, et al. High-Level Neuronal Expression of Abeta 1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation. *J Neurosci*. 2000; 20: 4050–4058. PMID: [10818140](https://pubmed.ncbi.nlm.nih.gov/10818140/)
22. Manson JC, Clarke AR, Hooper ML, Aitchison L, McConnell I, Hope J. 129/Ola mice carrying a null mutation in PrP that abolishes mRNA production are developmentally normal. *Mol Neurobiol*. 1994; 8: 121–127. PMID: [7999308](https://pubmed.ncbi.nlm.nih.gov/7999308/)
23. Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. *J Neurosci*. 2001; 21: 372–381. PMID: [11160418](https://pubmed.ncbi.nlm.nih.gov/11160418/)
24. Piccardo P, Manson JC, King D, Ghetti B, Barron RM. Accumulation of prion protein in the brain that is not associated with transmissible disease. *Proc Natl Acad Sci U S A*. 2007; 104: 4712–4717. PMID: [17360589](https://pubmed.ncbi.nlm.nih.gov/17360589/)
25. Kaye R, Head E, Sarsoza F, Saing T, Cotman CW, Nacula M, et al. Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. *Mol Neurodegener*. 2007; 2: 18 PMID: [17897471](https://pubmed.ncbi.nlm.nih.gov/17897471/)